# Sanara MedTech Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sanara MedTech Inc.). ## Overview Sanara MedTech Inc. is a U.S.-based medical technology company focused on products and services for surgical care, chronic wound care, and skincare. Its business is organized around Sanara Surgical and THP, combining surgical-site products, bone fusion products, and value-based wound care services across the care continuum in the United States. ## Products & services • CellerateRX Surgical activated collagen • BIASURGE advanced surgical solution • BiFORM bioactive moldable matrix • ALLOCYTE Plus advanced viable bone matrix • Value-based wound care and skincare services • Product development through Rochal Technologies - **Soft tissue repair products** (88%) — Collagen-based and surgical-site products used to support wound healing and irrigation in sterile settings. - **Bone fusion products** (12%) — Biologic and matrix products used in orthopedic and surgical bone grafting and fusion procedures. - **Value-based wound care services** (0%) — THP-related wound care and skincare services and programs delivered through provider partnerships. - **R&D and pipeline technologies** (0%) — Internal development work and product pipeline activities led by Rochal Technologies. - CellerateRX Surgical activated collagen - BIASURGE advanced surgical solution - BiFORM bioactive moldable matrix - ALLOCYTE Plus advanced viable bone matrix - Value-based wound care and skincare services - Product development through Rochal Technologies ## Customers The company sells primarily to hospitals and other acute care facilities that use its products in surgical and sterile care settings. It also serves wound care providers and other healthcare organizations that participate in value-based wound and skincare programs. Demand is driven by clinical adoption, procedure volumes, and the ability of products and services to fit into hospital and provider workflows. - **Hospitals and acute care facilities** (primary) — Buy soft tissue repair and bone fusion products for use in operating rooms and sterile environments. - **Wound care provider groups** (primary) — Adopt THP value-based wound care and skincare services to support patient management across care settings. - **Surgeons and procedural clinicians** (secondary) — Influence product selection for surgical-site management, irrigation, and bone grafting applications. - **Healthcare systems and provider networks** (secondary) — Evaluate products and services based on clinical outcomes, workflow fit, and total cost of care. - Hospitals buying surgical-site products for operating rooms - Acute care facilities using collagen and irrigation products - Wound care provider groups adopting THP programs - Clinicians and surgeons selecting products for procedure support - Healthcare organizations seeking lower-cost wound outcomes ## Geography Sanara MedTech operates primarily in the United States, where it sells through an expanding independent distribution network and direct clinical relationships. Its reported growth has been tied to increased market penetration and geographic expansion within new and existing U.S. markets. The company does not disclose a meaningful non-U.S. revenue mix in the provided materials. - United States is the core commercial market - Sales are expanded through independent distribution networks - Growth depends on penetration in new and existing U.S. markets - Operations and clinical adoption are centered in U.S. healthcare facilities ## Strategy The company is building a broader platform across surgical products, wound care, and skincare services, with THP positioned as a key growth initiative. It is also expanding distribution, developing new products through Rochal Technologies, and pursuing acquisitions and partnerships to support a value-based care model. - **Expand THP and value-based wound care services** (short-term) — This creates a services layer alongside products and broadens the company’s care continuum offering. - **Increase penetration of surgical products** (medium-term) — Higher adoption of core products supports scale in hospitals and acute care facilities. - **Build the product and technology pipeline** (medium-term) — New products and technologies can extend the portfolio and support future growth. - **Pursue acquisitions and strategic partnerships** (medium-term) — External growth can add capabilities, provider access, and service offerings. - Expand the independent distribution network in U.S. markets - Grow THP as a value-based wound and skincare platform - Use acquisitions to add capabilities and provider relationships - Advance the product pipeline through internal R&D - Broaden offerings across the surgical and wound care continuum ## Risks The business depends on clinical acceptance, reimbursement dynamics, and the ability to commercialize licensed and internally developed products. It also faces execution risk in acquisitions, debt compliance, and the buildout of THP, while product quality, intellectual property, and supply chain disruptions can affect adoption and continuity. - **Clinical acceptance and market adoption** [high] — Revenue depends on surgeons, hospitals, and providers adopting the products in routine care. - **Reimbursement and regulatory changes** [high] — Healthcare purchasing and service economics are influenced by labeling, marketing, and reimbursement rules. - **Acquisition and integration execution** [medium] — The THP strategy relies on acquisitions and partner relationships that may not deliver expected benefits. - **Debt and liquidity management** [high] — The company uses credit facilities and equity financing to fund growth and acquisitions. - **Dependence on third-party licensed products and supply** [medium] — Manufacturing, licensing, and distribution disruptions can interrupt sales and margins. - **Product quality and intellectual property** [medium] — Defects or IP disputes can limit commercialization and damage customer trust. - Clinical adoption risk if products fail to gain market acceptance - Reimbursement and regulatory risk in wound and surgical markets - Execution risk in THP buildout and acquisition integration - Dependence on third-party licensed technologies and manufacturers - Product quality or defect issues could damage demand and reputation ## Accounting Revenue is recognized when purchase orders are received and products are delivered, so shipment timing can affect quarterly results. Investors should also watch acquisition accounting, earnout liabilities, and intangible asset amortization, because these items can materially affect reported earnings and balance sheet values. - **Revenue recognition timing** — Quarterly revenue and gross profit - **Acquisition accounting and earnout liabilities** — Goodwill, intangibles, and noncash fair value gains/losses - **Intangible asset amortization** — Operating expenses and earnings - **Related-party transactions** — Balance sheet and governance transparency - **Estimates and purchase price allocation** — Acquisition accounting and future impairment risk - Point-in-time revenue recognition tied to order receipt and delivery - Quarterly revenue can shift with shipment timing and procedure demand - Purchase price allocation for acquisitions affects intangibles and goodwill - Earnout liabilities are remeasured at fair value each period - Intangible amortization and impairment can affect reported earnings --- *Last updated: 2026-04-29T04:57:33.433798+00:00*